FDA 505(b)(2) Policy Affirmed; Any Changes Will Be Too Late For Norvasc

FDA will reconsider whether approval of new salt formulations under the Sec. 505(b)(2) process is appropriate, but any changes will not prevent approval of a pending competitor to Pfizer's antihypertensive Norvasc